StemCells, Inc.
STEM announced today the results of a four-year observation study in
patients with neuronal ceroid lipofuscinosis (NCL), also referred to as Batten
disease, who had been transplanted with the Company's proprietary HuCNS-SC®
cells (purified human neural stem cells) in the initial Phase I study. Key
results include long-term evidence of safety, up to five years post
transplantation, for the surgical transplantation of the HuCNS-SC cells into
multiple sites in the brain and at doses of up to one billion cells. The study
results represent the first, and thus far only, multi-year data set following
transplantation of neural stem cells into human subjects, and supports the
feasibility of the Company's approach in multiple neurological disorders. The
data will be presented today by Nathan Selden, MD, PhD, FACS, FAAP, who was
co-principal investigator in the studies, at the Congress of Neurological
Surgeons Annual Meeting in San Francisco, California.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in